MedTrace Logo

A Study to Determine the Safety and Attack Rate of the Seasonal Flu in Healthy Volunteers

NCT04372719 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-05-04

No results posted yet for this study

Summary

This is a non-controlled, open-label, single-centre, dose-escalation study to determine the safety, infectivity and immunology of the potential novel influenza virus H3N2 challenge strain. The term 'challenge agent' used in this protocol refers to the Influenza virus H3N2 A/Belgium/4217/2015. The study utilises an adaptive study design and consists of 2 parts.

Conditions

  • Influenza, Human

Interventions

DRUG

H3N2

Sponsors & Collaborators

  • SGS Life Sciences, a division of SGS Belgium NV

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-02
Primary Completion
2016-12-28
Completion
2016-12-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04372719 on ClinicalTrials.gov